Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.34 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.34 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.33 |
| ▸ | CDK7 | P50613 | 1/20 | 0.31 |
| ▸ | CCNH | P51946 | 1/20 | 0.31 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18403238 | 0.83 | SMN1; SMN2 (0.37) | PSMB8PSMB9MAP3K12KDM4EALDH1A1 | |
| SCHEMBL15890100 | 0.81 | MAP3K12 (0.49) | MAP3K12KDM4EALDH1A1 | |
| SCHEMBL17387977 | 0.77 | MAP3K12 (0.44) | PSMB8PSMB9MAP3K12KDM4E | |
| SCHEMBL15882679 | 0.74 | PLAT (0.39) | MAP3K12 | |
| SCHEMBL17454466 | 0.72 | PSMB8 (0.45) | PSMB8PSMB9MAP3K12ALDH1A1PDK1 | |
| SCHEMBL27217239 | 0.72 | KDM1A (0.39) | PSMB8PSMB9 | |
| SCHEMBL10203516 | 0.69 | PSMB8 (0.45) | PSMB8PSMB9KDM4EALDH1A1PDK1 | |
| SCHEMBL19902361 | 0.69 | RIPK1 (0.49) | PSMB8PSMB9MAP3K12PDK1PDK2 | |
| SCHEMBL2795047 | 0.68 | PSMB8 (0.44) | PSMB8PSMB9MAP3K12ALDH1A1PDK1 | |
| SCHEMBL15890082 | 0.68 | MAP3K12 (0.47) | MAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550777-B2 | 3-substituted pyrazoles and use as DLK inhibitors | GENENTECH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550777-B2 | 3-substituted pyrazoles and use as DLK inhibitors | GENENTECH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160002228-A1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | GENENTECH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002228-A1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | PDXK, NLK, PDK3 | PSMB8 3668/4885PSMB9 3451/4885MAP3K12 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.